19937 results for «»
19937 results
Optimising CTO outcomes by lesion selection
21 May 2025 – From EuroPCR 2025
Optimize chronic total occlusion (CTO) PCI outcomes through lesion selection strategies. This session reviews coronary calcium patterns via CT, target vessel considerations, distal vessel remodeling, imaging-guided versus conventional approaches, and complex lesion cases.
Challenging scenarios in acute coronary syndrome
20 May 2025 – From EuroPCR 2025
This session presents challenging acute coronary syndrome (ACS) cases with unusual presentations and complications. Learn from cases involving myocarditis mimics, coronary aneurysms, rescue fibrinolysis during PCI, and STEMI complicated by cardiogenic shock, highlighting diagnostic and therapeutic nuances.
How to successfully approach CTO interventions: a step-by-step approach
22 Oct 2025 – From EuroPCR 2025
Elliot Smith, Thomas Hovasse and Roberto Garbo discuss a comprehensive, step-by-step approach to CTO interventions, providing structured guidance on navigating CTOs in a safe and effective way.
The discussion begins with angiographic assessment, emphasising the importance of identifying key anatomical features upfront. Based on this evaluation, operators determine...
How to manage coronary artery disease in TAVI candidates?
20 May 2025 – From EuroPCR 2025
Martine Gilard, Antonio Mangieri, and Marco Barbanti explore the strategy for handling coronary artery disease in patients undergoing TAVI. Is coronary angiography always required beforehand? Should PCI be performed in all cases—and if so, when? This exchange offers key insights to help guide your decisions on...
What are the fundamentals of an upfront two-stent strategy for bifurcation PCI?
21 May 2025 – From EuroPCR 2025
Nicola Ryan explores the fundamentals of an upfront two-stent strategy in bifurcation PCI with Dejan Milasinovic. When the side branch shows significant, high-grade stenosis or extensive disease, direct treatment - via POBA, DCB, or a second stent - may be preferred. Anatomy guides the decision between...
Repair and replace: latest insights in transcatheter treatment of mitral and tricuspid regurgitation
20 May 2025 – From EuroPCR 2025
Join Michael Mullen, Federico De Marco, and Philipp Lurz as they discuss the latest breakthroughs in the treatment of mitral and tricuspid regurgitation at EuroPCR 2025. In this roundtable session, they delve into both repair and replacement techniques, offering insights into new systems and their impact...
How to efficiently and safely manage calcified left main disease?
21 May 2025 – From EuroPCR 2025
Nicola Ryan and Flavio Ribichini explore the complexities of calcified left main stem disease, emphasizing the critical role of intracoronary imaging in improving patient outcomes. They discuss the practical use of mechanical circulatory support and debate stenting strategies, offering expert insights on when single or dual...
How to manage treatment dilemmas in STEMI patients with multivessel disease?
20 May 2025 – From EuroPCR 2025
Managing STEMI patients with multivessel disease is a complex challenge evolving rapidly thanks to new clinical evidence. Angela Mcinerney, Natalia Pinilla, and Matthias Götberg explore how findings from the COMPLETE trial and its intracoronary imaging substudy are reshaping treatment strategies.
Their discussion highlights the role of intracoronary...
Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study
20 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).
The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable...
Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study
21 May 2025 – From EuroPCR 2025
Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.
They review the trial design, patient characteristics, and results, comparing outcomes with...
What is the latest in DCB practice?
21 May 2025 – From EuroPCR 2025
Robert Byrne and Bruno Scheller explore the current role of drug-coated balloon (DCB) angioplasty nearly two decades after its initial clinical use. This discussion covers when and how to apply DCB angioplasty effectively in everyday practice, focusing on lesion preparation for de novo coronary disease and...
Preventing distal particles embolization after DCB angioplasty
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Aloke Finn and Antonio Colombo share their insights on a specific and often overlooked complication of drug-coated balloon (DCB) angioplasty: particulate embolization.
They begin by clarifying the distinction between this phenomenon and traditional distal embolization, explaining that particulate embolization is iatrogenic and device-related—it is...
Vulnerable plaque PCI after PREVENT
22 May 2025 – From EuroPCR 2025
This interview with Michael Haude and Thomas Cuisset explores findings from the PREVENT trial, which included over 1,600 patients with vulnerable, physiologically non-significant plaques identified by IVUS.
Patients were randomised to optimal medical therapy (OMT) alone or OMT plus preventive PCI. While the composite endpoint favoured the PCI...
What are the emerging indications for TAVI in 2025?
22 May 2025 – From EuroPCR 2025
Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux discuss emerging indications for TAVI in 2025. They review recent evidence on asymptomatic severe aortic stenosis, highlighting four randomised trials—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—that show TAVI or surgical AVR reduces hospitalisations for heart failure and trends toward...
Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis
21 May 2025 – From EuroPCR 2025
Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.
Patients with under-expanded valves faced higher risks...
What are the essentials of the provisional strategy for non-left main true bifurcation lesions?
21 May 2025 – From EuroPCR 2025
Giuseppe Di Gioia and Jens Flensted Lassen explore the essentials of the provisional stenting strategy for non-left main true bifurcation lesions. This stepwise approach offers simplicity while preserving flexibility: start with one stent in the main vessel, and keep the option open for a second if...
First guidelines for the treatment of LM disease issued by SOLACI and SIAC
22 May 2025 – From EuroPCR 2025
During EuroPCR 2025, Cleverson Zukowski and Pablo Lamelas introduce a landmark initiative: the first clinical guidelines for left main disease specifically developed for Latin America.
Published by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC), these recommendations aim to support...
How will EARLY-TAVI and NOTION-3 impact TAVI practice?
21 May 2025 – From EuroPCR 2025
When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...
Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies
22 May 2025 – From EuroPCR 2025
Stroke remains one of the most feared complications of TAVI—for both patients and physicians. In this EuroPCR 2025 video interview, Bernard Prendergast and Rajesh Kharbanda examine the role of cerebral protection during TAVI procedures, in light of two randomised trials: PROTECTED TAVR and BHF PROTECT-TAVI. While...
Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
21 May 2025 – From EuroPCR 2025
In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...
